✦ LIBER ✦

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

✍ Scribed by Youn H. Kim; Michael Girardi; Madeleine Duvic; Timothy Kuzel; Brian K. Link; Lauren Pinter-Brown; Alain H. Rook

Book ID: 116586683
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 491 KB
Volume: 63
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2009.12.052

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I Trial of Toll-Like Receptor 9 Ag

Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma

✍ Leonard, J. P.; Link, B. K.; Emmanouilides, C.; Gregory, S. A.; Weisdorf, D.; An 📂 Article 📅 2007 🏛 American Association for Cancer Research 🌐 English ⚖ 196 KB

Phase II Trial of a Toll-Like Receptor 9

Phase II Trial of a Toll-Like Receptor 9-Activating Oligonucleotide in Patients With Metastatic Melanoma

✍ Pashenkov, M.; Goess, G.; Wagner, C.; Hormann, M.; Jandl, T.; Moser, A.; Britten 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 777 KB

Intratumoural injection of the toll-like

Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial

✍ Schmidt, J; Welsch, T; Jäger, D; Mühlradt, P F; Büchler, M W; Märten, A 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 205 KB

Phase Ib trial of the Toll-like receptor

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

✍ Machiels, Jean-Pascal; Kaminsky, Marie-Christine; Keller, Ulrich; Brümmendorf, T 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 333 KB

9148 Phase 1 study of the toll-like rece

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

✍ Smith, D.A.; Conkling, P.; Richards, D.; Alemany, C.; Boyd, T.; Garbo, L.; Wu, H 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB